Silexion Therapeutics (SLXN) Common Equity (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Common Equity of $291000.0 for Q1 2026, down 88.75% year-over-year from $2.6 million in Q1 2025, and down 88.82% quarter-over-quarter from $2.6 million in Q4 2025.
Silexion Therapeutics (SLXN) Common Equity (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $291000.0 for Q1 2026.
- In Q1 2026, Common Equity fell 88.75% year-over-year to $291000.0; the TTM figure through Mar 2026 stood at $291000.0 (down 88.75% YoY), while the FY2025 annual figure was $2.6 million, up 165.25% from the prior year.
- Common Equity for Q1 2026 stood at $291000.0, down from $2.6 million in the prior quarter.
- The five-year high for Common Equity was $7.0 million in Q3 2025, with the low at -$4.6 million in Q3 2023.
- The 4-year median for Common Equity is $950500.0 (2024), against an average of $795833.3.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 232.92% in 2024, then surged 252.37% in 2025.
- Silexion Therapeutics' Common Equity stood at $3.0 million in 2023, then plunged by 232.92% to -$4.0 million in 2024, then jumped by 165.25% to $2.6 million in 2025, then plunged by 88.82% to $291000.0 in 2026.
- Business Quant data shows SLXN's Common Equity at $291000.0 in Q1 2026, $2.6 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,000.00 |
| Mar 31, 2026 | 291,000.00 |
| Dec 31, 2025 | 2.60 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 2.59 Mn |
| Dec 31, 2024 | -3.99 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | -4.65 Mn |
| Jun 30, 2023 | 5.42 Mn |